SkySea Pharmaceutical
Innovative pharmaceutical solutions targeting diseases without basic cures, featuring cutting-edge chronal antibodies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | JPY35.0m | Seed | |
| Total Funding | 000k | ||
Related Content
SkySea Pharma is a pharmaceutical company focused on developing innovative treatments for diseases that currently lack basic cures. The company operates in the pharmaceutical and biotechnology market, primarily serving healthcare providers, research institutions, and patients in need of advanced medical solutions. SkySea Pharma's business model revolves around the research, development, and commercialization of novel drugs, including their flagship product, antioxytosine chronal antibodies, which have been recognized in the International Journal of Natural Sciences. Revenue is generated through the sale of these pharmaceutical products, licensing agreements, and partnerships with other healthcare organizations. The company aims to make a significant social contribution by addressing unmet medical needs and improving patient outcomes.
Keywords: pharmaceutical, biotechnology, chronal antibodies, antioxytosine, innovative treatments, healthcare, research, commercialization, licensing, patient outcomes.